Skip to search formSkip to main contentSkip to account menu

Celgene

An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve…
Review
2016
Review
2016
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Despite representing a breakthrough in the treatment of immune-mediated rheumatic diseases, the direct costs of biotechnological… 
Highly Cited
2015
Highly Cited
2015
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune… 
2014
2014
Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC…
Review
2012
Review
2012
Chronic Myeloid Leukemia Stem Cell Biology
Leukemia progression and relapse is fueled by leukemia stem cells (LSC) that are resistant to current treatments. In the… 
2012
2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
Our previous studies have shown that lowering the dose of pegylated liposomal doxorubicin (PLD) and bortezomib in combination… 
Review
2011
Review
2011
Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Review
2011
Review
2011
Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
2009
2009
ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy…
Abstract 749 Background: Anemia is frequently observed in multiple myeloma (MM) patients and can result from cumulative marrow… 
Review
2004
Review
2004
CC-5013 (Celgene).
Celgene, in collaboration with the National Cancer Institute, is developing CC-5013, the lead compound in a series of thalidomide… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)